Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Proteomics International Laboratories Ltd. ( (AU:PIQ) ) is now available.
Proteomics International Laboratories Ltd has announced the presentation of its PromarkerEso diagnostic test results at the World Congress for Esophageal Diseases. The test, which detects early stages of esophageal adenocarcinoma with high accuracy, is now available across Australia through telehealth consultations and physician referrals. This development could significantly improve health outcomes by enabling earlier diagnosis and treatment of esophageal cancer, a condition often diagnosed too late for effective intervention.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing innovative diagnostic tests to improve health outcomes. The company is known for its first-in-class blood tests, such as PromarkerEso, which targets early detection of diseases like esophageal adenocarcinoma.
Average Trading Volume: 370,276
Technical Sentiment Signal: Sell
Current Market Cap: A$47.47M
See more insights into PIQ stock on TipRanks’ Stock Analysis page.